These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623 [TBL] [Abstract][Full Text] [Related]
44. The antimicrobial peptides LL-37, KR-20, FK-13 and KR-12 inhibit the growth of a sensitive and a metronidazole-resistant strain of Trichomonas vaginalis. Ramírez-Ledesma MG; Rodríguez MC; Alva-Murillo N; Avila EE Parasitol Res; 2022 Dec; 121(12):3503-3512. PubMed ID: 36171407 [TBL] [Abstract][Full Text] [Related]
45. [Imidazoles in the treatment of infections due to parasitic protozoa "lumenals". (T. vaginalis, Giardia intestinalis, E. histolytica--general principles)]. Grassi GG G Ital Chemioter; 1976; 23(1):41-6. PubMed ID: 196967 [No Abstract] [Full Text] [Related]
49. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. Van Der Pol B; Williams JA; Orr DP; Batteiger BE; Fortenberry JD J Infect Dis; 2005 Dec; 192(12):2039-44. PubMed ID: 16288365 [TBL] [Abstract][Full Text] [Related]
50. Effects of SQ109 on Trichomonas vaginalis. de Souza TG; Granado R; Benaim G; de Souza W; Benchimol M Exp Parasitol; 2023 Jul; 250():108549. PubMed ID: 37196704 [TBL] [Abstract][Full Text] [Related]
51. Iron-saturated lactoferrin and pathogenic protozoa: could this protein be an iron source for their parasitic style of life? Ortíz-Estrada G; Luna-Castro S; Piña-Vázquez C; Samaniego-Barrón L; León-Sicairos N; Serrano-Luna J; de la Garza M Future Microbiol; 2012 Jan; 7(1):149-64. PubMed ID: 22191452 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and antiprotozoal activity of nitazoxanide-N-methylbenzimidazole hybrids. Soria-Arteche O; Hernández-Campos A; Yépez-Mulia L; Trejo-Soto PJ; Hernández-Luis F; Gres-Molina J; Maldonado LA; Castillo R Bioorg Med Chem Lett; 2013 Dec; 23(24):6838-41. PubMed ID: 24183540 [TBL] [Abstract][Full Text] [Related]
54. Keto-acid oxidoreductases in the anaerobic protozoa. Upcroft JA; Upcroft P J Eukaryot Microbiol; 1999; 46(4):447-9. PubMed ID: 10461388 [TBL] [Abstract][Full Text] [Related]
55. Dealing with trichomoniasis. Young F J Fam Health Care; 2006; 16(5):153-5. PubMed ID: 17139977 [TBL] [Abstract][Full Text] [Related]
56. Trichomoniasis--an important cofactor of human immunodeficiency virus infection. Serwin AB; Koper M Przegl Epidemiol; 2013; 67(1):47-50, 131-4. PubMed ID: 23745375 [TBL] [Abstract][Full Text] [Related]
57. Strategies for Prevention and Treatment of Trichomonas vaginalis Infections. Bouchemal K; Bories C; Loiseau PM Clin Microbiol Rev; 2017 Jul; 30(3):811-825. PubMed ID: 28539504 [TBL] [Abstract][Full Text] [Related]
58. In vitro effects of various plants extracts on the growth of Trichomonas vaginalis. Sharafi SM; Yousefi M; Yousefi HA; Asghari G; Darani HY Infect Disord Drug Targets; 2013 Oct; 13(5):322-7. PubMed ID: 24712672 [TBL] [Abstract][Full Text] [Related]
59. Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity. Muzny CA; Van Gerwen OT; Kissinger P Curr Opin Infect Dis; 2020 Feb; 33(1):73-77. PubMed ID: 31789671 [TBL] [Abstract][Full Text] [Related]
60. Anaerobic energy metabolism in human microaerophile parasites. Carvalho-de-Araújo AD; Carvalho-Kelly LF; Meyer-Fernandes JR Exp Parasitol; 2023 Apr; 247():108492. PubMed ID: 36841468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]